Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Losartan Versus Hydrochlorothiazide in Reversing Remodeling of Small Arteries in Pre-Hypertensive Pre-Diabetic Subjects

This study has been terminated.
(Few subjects recruited, sponsor withdrew support.)
Merck Frosst Canada Ltd.
Information provided by (Responsible Party):
Ernesto L. Schiffrin, Sir Mortimer B. Davis - Jewish General Hospital Identifier:
First received: October 13, 2006
Last updated: May 18, 2015
Last verified: May 2015
This randomized, double-blind, parallel group, two-centre pilot study will test the hypothesis that subjects who are otherwise healthy but fulfill the criteria for a diagnosis of pre-hypertension and pre-diabetes will have regression or reduced progression of hypertension-associated changes in their resistance arteries if their blood pressure is controlled for 6 months with losartan, whereas similar subjects whose blood pressure is equally well controlled using hydrochlorothiazide will have significantly less improvement of the changes in their resistance arteries.

Condition Intervention Phase
Drug: losartan, hydrochlorothiazide
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double-blind, Randomized, Parallel Design Study Comparing Effectiveness of Losartan vs. Hydrochlorothiazide in Reversing or Preventing the Progression of the Remodeling of Resistance Arteries in Pre-hypertensive Pre-diabetic Subjects

Resource links provided by NLM:

Further study details as provided by Sir Mortimer B. Davis - Jewish General Hospital:

Primary Outcome Measures:
  • Effect of 6 months of losartan or hydrochlorothiazide on media/lumen ratio of gluteal subcutaneous resistance arteries in otherwise normal subjects who fulfill criteria for pre-hypertension and pre-diabetes [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • Safety and tolerability of 6 month therapy with losartan or hydrochlorothiazide, and effect on media thickness, lumen diameter and vascular function of gluteal subcutaneous resistance arteries, and serum and tissue inflammatory markers in same subjects [ Time Frame: 6 months ]

Enrollment: 1
Study Start Date: March 2007
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Losartan treatment
Drug: losartan, hydrochlorothiazide
Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
Other Name: Cozaar, Apo-hydro
Active Comparator: 2
Hydrochlorothiazide, 12.5-25 mg per day once a day for 6 months
Drug: losartan, hydrochlorothiazide
Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
Other Name: Cozaar, Apo-hydro

  Show Detailed Description


Ages Eligible for Study:   25 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Prehypertensive prediabetic subjects (25-70 years old) defined as otherwise normal subjects with a mean SiSBP of 120-139 mmHg and fasting blood glucose of 6.1-6.9 mmol/L or impaired glucose tolerance on oral glucose tolerance test (OGTT) at screening and after two weeks of placebo therapy (Week -2)

Exclusion Criteria:

  • Hypertension or clinically significant renal disease
  • Cerebrovascular accident within the past year, or current transient ischemic attacks
  • Myocardial infarction within the past year; percutaneous coronary angioplasty or coronary artery bypass surgery within last 6 months
  • Clinically significant AV conduction disturbances and/or arrhythmias (e.g. second- or third-degree AV block; sick-sinus syndrome or clinically significant bradycardia- resting heart rate < 45 beats/minute), tachyarrhythmias; clinically significant arrhythmias, presence of accessory bypass tract (e.g. Wolff-Parkinson-White syndrome)
  • Angina pectoris
  • Current or prior history of heart failure or known left ventricular ejection fraction <40%
  • History of unexplained syncope or known syncopal disorder (e.g., Stokes-Adams Syndrome)
  • Known history of hemodynamically significant obstructive valvular disease or hypertrophic cardiomyopathy
  • Use of agents that may cause alteration of blood pressure is prohibited. This includes nitrates, or alpha or beta-blockers. Calcium channel blockers are allowed as second line therapy if hypertension develops during the study Major psychotropic agents and antidepressants are not permitted
  • Cimetidine is not permitted (famotidine and ranitidine and proton pump inhibitors are allowed).
  • NSAIDs are permitted if taken on a stable regimen. Aspirin in small doses (< 1 g/day) as cardioprotective agent and acetaminophen are permitted
  • Oral or inhaled steroids, ACTH, immunosuppressants or lithium are not allowed
  • Serum creatinine concentration >200 μmol/L (adjusted for age and weight)
  • Urine dipstick or microscopic findings suggestive of significant renal or other disease.
  • Hematuria should be evaluated, the etiology established/documented, and treatment rendered as appropriate prior to entry
  • Off-treatment serum potassium concentration >5.5 mmol/L or <3.5 mmol/L
  • AST (SGOT) or ALT (SGPT) >2 x normal upper limit
  • Clinically significant laboratory values outside of the established normal range including but not limited to the following parameters: hemoglobin, platelet count or white blood cell count
  • Known hypersensitivity or contraindication to losartan or thiazide diuretics
  • History of clinically important malabsorption or gastrointestinal resection
  • Current urinary tract infection
  • Smoking 10 cigarettes or more.
  • Pregnancy or lactating females. Females of childbearing age who are not surgically sterilized and are using effective contraception may enter only if an exclusionary pregnancy test is done within 72 hours of the first double-blind dose of test agent. Pregnancy tests will then be done monthly throughout the study.
  • Vasculitis or vasculopathy: collagen-vascular diseases, chronic hepatitis B antigenemia, circulating immune complexes, complement disorders, amyloidosis, scleroderma, etc. Neoplasms, Acquired Immunodeficiency Syndrome (AIDS), or HIV positive
  • Bleeding or platelet disorder
  • Known absence of one kidney
  • Subjects abusing or who within past two years abused alcohol or other drug substances
  • Mentally or legally incapacitated subjects
  • Subjects who have participated in another investigational drug trial, including those using marketed drugs (i.e. patient has signed a consent form), within the 28 days prior to start of placebo therapy
  • Subjects who, in the opinion of the investigator, will not cooperate fully, keep appointments or are unreliable
  • Inability or unwillingness to sign the Patient Consent Form
  • Phase V of Korotkoff sounds cannot be detected
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00388388

Canada, Quebec
Cardiovascular Prevention Centre, Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Sponsors and Collaborators
Sir Mortimer B. Davis - Jewish General Hospital
Merck Frosst Canada Ltd.
Principal Investigator: Ernesto L. Schiffrin, MD, PhD Physician-Chief, SMBD - Jewish General Hospital & Professor of Medicine, McGill University
  More Information

Additional Information:
Responsible Party: Ernesto L. Schiffrin, Physician-in-Chief, Sir Mortimer B. Davis - Jewish General Hospital Identifier: NCT00388388     History of Changes
Other Study ID Numbers: CPC030
Study First Received: October 13, 2006
Last Updated: May 18, 2015

Keywords provided by Sir Mortimer B. Davis - Jewish General Hospital:
Resistance arteries
angiotensin receptor blocker
thiazide diuretic

Additional relevant MeSH terms:
Prediabetic State
Glucose Intolerance
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Arrhythmia Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists processed this record on April 25, 2017